Clinical Trial Update: A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating efficacy and safety of sunitinib in advanced well-differentiated pancreatic neuroendocrine tumors has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Well-differentiated Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Well-differentiated Pancreatic Neuroendocrine Tumor | Phase 4 | Status: COMPLETED | Results posted: 2017-05-19